Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Dendritic cells are immune system commanders, spotting foreign antigens and rallying T cells for defense. In dendritic cell vaccines, scientists extract these cells from tumors, mix them with tumor antigens, and reinject them to enhance the body's anti-tumor response. At Alfa Cytology, we boast a cutting-edge platform in cancer vaccine development. With our extensive experience, we are confident in delivering top-tier development services for dendritic cell-based cancer vaccines.
Dendritic cells serve as primary antigen presenters in the immune system, coordinating intricate responses against cancer cells. Through cross-presentation, they communicate the presence of antigens to CD4 and CD8 T cells, mobilizing our body's defense mechanisms effectively. Initially found in blood and peripheral tissues in an inactive state, dendritic cells undergo significant phenotypic and functional changes upon antigen encounter, migrating to lymphoid tissues to initiate targeted immune responses. Additionally, their interaction with natural killer cells augments our immune system's capacity to combat tumor cells.
Fig.1 Concept of DC Vaccination. (Zheng, Y., et al.,2023)
Dendritic cell cancer vaccines, as personalized therapies, can be tailored to the specific characteristics of individual tumors, allowing for more precise and targeted tumor therapeutics. Alfa Cytology boasts a dedicated team of scientifically adept professionals to facilitate the development of tumor cell cancer vaccines.
At Alfa Cytology, a leader in vaccine synthesis, we're dedicated to researching and developing vaccines for all types of dendritic cell cancers. Currently, we're conducting studies on various cancers, including but not limited to, the following types.
There are multiple processes involved in the development of a dendritic cell cancer vaccine, and Alfa Cytology is ready to help you with your cancer vaccine development. Here are the key steps in the development of a dendritic cell cancer vaccine.
Tumor Sample Collection and Processing
Tumor tissue or cells are collected, treated, and stored under optimal conditions to preserve their integrity and vitality.
Extraction and Isolation of Dendritic Cells
Dendritic cells were extracted from tumor samples by cell sorting techniques, density gradient centrifugation, or magnetic bead sorting.
Culture and Activation of Dendritic Cells
Dendritic cell numbers were amplified through culture, while concurrently activating them to effectively recognize and present tumor antigens to the immune system.
Antigen Selection and Loading
Tumor samples undergo analysis via molecular biology and bioinformatics to pinpoint tumor-specific antigens. These antigens are then loaded onto dendritic cells' surfaces or internal compartments to trigger immune system activation.
Recombination of Dendritic Cells and Antigens
Activated dendritic cells are fused with tumor antigens and subjected to processing either in vitro or in vivo to guarantee efficient presentation to T cells, thereby triggering the activation of the immune response.
Design and conduct preclinical studies to evaluate the safety and efficacy of dendritic cell vaccines.
Professional and well-trained technical team.
Advanced experimental equipment.
Empowering success through cooperation.
Strict quality control system.
Alfa Cytology has led in vaccine development, specializing in cancer vaccine services for years. Backed by seasoned experts and cutting-edge platforms, we ensure quality services. For further details on our services, please don't hesitate to contact us for further information.
Reference
